An interventional study of standard verbal instructions and Explanatory leaflets in Degree of Adherence of Symptomatic OLP Patients to Their Medications, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
This trial will assess the effect of adjunctive use of explanatory leaflet or daily text message reminder compared to standard instructions alone in degree of adherence of symptomatic OLP patients to their medications.
Symptomatic OLP poses therapeutic challenges due to its chronicity; repeated medication application, prolonged contact time, and sustained use of topical and systemic therapies over weeks or months. Poor adherence is a barrier to symptom control. Adherence is affected by regimen complexity, concerns about corticosteroid use, inconvenience, and patient frustration with recurrence .The aim of the present study is to assess the effect of adjunctive use of explanatory leaflet or daily text message reminder compared to standard instructions alone in degree of adherence of symptomatic oral lichen planus (OLP) patients to their medications.
Cairo University is the lead sponsor of 4,909 studies on the registry; 1,445 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One group will receive standard instructions augmented with patient education regarding the nature of the disease, objectives of the treatment, form of the medication and expected adverse effects during the first visit. Topical Corticosteroid will be prescribed four times daily or Systemic Corticosteroid will be prescribed once daily according to condition
Behavioral: standard verbal instructions · Behavioral: Explanatory leaflets
The second group will receive standard instructions augmented with daily text message reminder. Topical Corticosteroid will be prescribed four times daily and Systemic Corticosteroid will be prescribed once daily according to condition.
Behavioral: standard verbal instructions · Behavioral: text msgs
The third group will receive standard instructions. Topical Corticosteroid will be prescribed four times daily and Systemic Corticosteroid will be prescribed once daily according to the condition.
Behavioral: standard verbal instructions
this will be applied to all three groups
Explanatory leaflet; the instructions augmented with patient education regarding the nature of the disease, objectives of the treatment, form of the medication and expected adverse effects during the first visit
daily text message reminder to apply the medicine
Degree of adherence [objective assessment] will be assessed by weighing tubes or counting pills.
Objective adherence assessments by weighing tubes or counting pills provide a reliable and accurate measure of patient behavior.
Time frame: from enrollment to the end of treatment at 4 weeks
Degree of adherence [subjective assessment] will be reported by patients using Morisky Medication Adherence Scale
Degree of adherence will be reported by patients using Morisky Medication Adherence Scale at baseline, weekly for 4 weeks or till healing. Morisky Medication Adherence Scale captures medication-taking behaviors and identify common barriers to adherence.
Time frame: At baseline, weekly for 4 weeks or till healing. (From enrollment to the end of treatment at 4 weeks)
Pain intensity will be measured using Visual analogue scale (VAS).
Pain intensity will be measured using Visual analogue scale (VAS), VAS is a self-reported pain score ranging from 0 to 10 at baseline, daily for the first week, then weekly for the remaining 3 weeks or till healing.
Time frame: At baseline, daily for the first week, then weekly for the remaining 3 weeks or till healing (From enrollment to the end of treatment at 4 weeks).
Clinical improvement will be measured using Thongprasom et al. scoring system.
Clinical improvement will be measured using Thongprasom et al. scoring system at baseline, and weekly for 4 weeks or till healing. Thongprasom et al. scale scores lesions as follows: 0, no lesions, normal mucosa; 1, Mild white striae, no erythematous area; 2, White striae with atrophic area \< 1 cm2; 3, White striae with atrophic area \> 1 cm2; 4, White striae with erosive area \< 1 cm2 and 5, White striae with erosive area \> 1 cm2.
Time frame: At baseline, and weekly for 4 weeks or till healing. (From enrollment to the end of treatment at 4 weeks)
Recurrence rate
Number of attacks
Time frame: At week 8 and week 12
Start is estimated for Oct 2026; primary completion for Jun 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.